"Sulfonamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that contain the structure SO2NH2.
| Descriptor ID |
D013449
|
| MeSH Number(s) |
D02.065.884 D02.886.590.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonamides".
Below are MeSH descriptors whose meaning is more specific than "Sulfonamides".
This graph shows the total number of publications written about "Sulfonamides" by people in this website by year, and whether "Sulfonamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 1 | 1 | 2 |
| 2000 | 4 | 2 | 6 |
| 2001 | 1 | 1 | 2 |
| 2002 | 4 | 0 | 4 |
| 2003 | 7 | 3 | 10 |
| 2004 | 2 | 2 | 4 |
| 2005 | 2 | 5 | 7 |
| 2006 | 4 | 6 | 10 |
| 2007 | 8 | 2 | 10 |
| 2008 | 8 | 3 | 11 |
| 2009 | 3 | 4 | 7 |
| 2010 | 4 | 3 | 7 |
| 2011 | 6 | 6 | 12 |
| 2012 | 8 | 2 | 10 |
| 2013 | 9 | 3 | 12 |
| 2014 | 9 | 7 | 16 |
| 2015 | 2 | 5 | 7 |
| 2016 | 5 | 4 | 9 |
| 2017 | 4 | 1 | 5 |
| 2018 | 2 | 2 | 4 |
| 2019 | 8 | 1 | 9 |
| 2020 | 4 | 4 | 8 |
| 2021 | 5 | 6 | 11 |
| 2022 | 0 | 5 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 4 | 4 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonamides" by people in Profiles.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Venetoclax Induces BCL-2-Dependent Treg to TH17 Plasticity to Enhance the Antitumor Efficacy of Anti-PD-1 Checkpoint Blockade. Cancer Immunol Res. 2024 Aug 01; 12(8):1074-1089.
-
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
-
Effectiveness of tenapanor for treating hyperphosphatemia in patients receiving dialysis: a plain language summary of the OPTIMIZE study. Curr Med Res Opin. 2024 Aug; 40(8):1335-1343.
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
-
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 02 20; 14(1):32.
-
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 04; 99(4):615-624.
-
Tenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study. Kidney360. 2024 May 01; 5(5):732-742.
-
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 08 19; 402(10402):641-654.
-
Peri-operative Reparixin therapy resulted in 50% 5-year insulin independence rate: The University of Chicago experience. Clin Transplant. 2023 05; 37(5):e14981.